<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745470</url>
  </required_header>
  <id_info>
    <org_study_id>H-1507-038-686</org_study_id>
    <nct_id>NCT02745470</nct_id>
  </id_info>
  <brief_title>Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain</brief_title>
  <official_title>Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain Measured by Functional MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims this study is to explore the effect of a GLP-1 receptor agonist on the degree of
      brain activation and connectivity obtained by functional magnetic resonance imaging in lean
      and obese type 2 diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifteen lean [BMI(body mass index) less than 23 kg/m2] type 2 diabetes subjects and fifteen
      obese (BMI more than 26 kg/m2) subjects with type 2 diabetes treated by diet and/or
      metformin, SU(sulfonylurea), DPP4-inhibitors(Dipeptidyl peptidase-4 inhibitor) will be
      recruited. Every subject will be studied on 2 separate days in random order with 1-2 week
      intervals. These participants will be injected either normal saline or 10 mcg of lixisenatide
      in a cross-over fashion. Neuroimaging composed with resting-12-min, visual stimulation
      task-12-min, T1-5-min, and diffusion tensor image-12-min will be proceeded. Ad lib buffet
      will be provided to every participant and the intake will be measured. Surveys about appetite
      and mood will be done before and after neuroimaging test and buffet eating.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of BOLD (Blood oxygenation level-dependent) signal in hypothalamus</measure>
    <time_frame>10min (40 min after injection)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole brain connectivity</measure>
    <time_frame>20min (50 min after injection)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>appetite change</measure>
    <time_frame>-30min, 45min(after fMRI), 70min(after buffet)</time_frame>
    <description>Visual analoge scale-questionnaire consisting of 8 questions (Flint, Raben, Blundell, &amp; Astrup, 2000)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mood change</measure>
    <time_frame>-30min, 45min(after fMRI), 70min(after buffet)</time_frame>
    <description>Visual analoge scale-questionnaire consisting of 16 questions (Boggieo et al., 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intake of food in the buffet</measure>
    <time_frame>50min</time_frame>
    <description>It will be provided quantified juice and milk , boiled eggs, bread , bananas and chocolate bars.
Participants may eat freely for 20 minutes. Then measure the intake of participants.
Compares whether the difference in food intake pattern .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Lixisenatide injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention : Lyxumia® pen injection 10 microgram (Lixisenatide) subcutaneous injection 30 minutes before functional MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control : normal saline 0.3 cc subcutaneous injection before functional MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide</intervention_name>
    <description>Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)</description>
    <arm_group_label>Lixisenatide injection</arm_group_label>
    <other_name>Lyxumia® pen injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline injection before performing fMRI</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Normal saline injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≤ 23kg/m2 or BMI ≥ 26kg/m2

          -  participants with diabetes treated by diet or oral antidiabetic drug, HbA1c less than
             8.5%

        Exclusion Criteria:

          -  Those who diagnosed by Type 1 diabetes

          -  History of insulin therapy

          -  Aspartate aminotransferase(AST) or Alanine transaminase(ALT) &gt;2.5 times of upper
             normal reference range

          -  Estimated Glomerular Filtration Rate(eGFR) &lt;30 mL/min/1.73m2

          -  Those who can't be performed MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Min Cho, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Associate Professor Division of Endocrinology and Metabolism Department of Internal Medicine Seoul National University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2016</study_first_submitted>
  <study_first_submitted_qc>April 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lean/obese diabetes mellitus</keyword>
  <keyword>functional MRI</keyword>
  <keyword>GLP-1</keyword>
  <keyword>appetite</keyword>
  <keyword>activation of brain</keyword>
  <keyword>connectivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

